NO20071921L - Fremgangsmater for behandling av epileptogenese og epilepsi - Google Patents
Fremgangsmater for behandling av epileptogenese og epilepsiInfo
- Publication number
- NO20071921L NO20071921L NO20071921A NO20071921A NO20071921L NO 20071921 L NO20071921 L NO 20071921L NO 20071921 A NO20071921 A NO 20071921A NO 20071921 A NO20071921 A NO 20071921A NO 20071921 L NO20071921 L NO 20071921L
- Authority
- NO
- Norway
- Prior art keywords
- group
- phenyl
- alkyl
- epilepsy
- methods
- Prior art date
Links
- 206010015037 epilepsy Diseases 0.000 title abstract 2
- 230000008579 epileptogenesis Effects 0.000 title abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 239000011630 iodine Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Denne oppfinnelsen er rettet mot fremgangsmåter for forebygging, behandling, reversering, inhibering eller arrestering av epilepsi og epileptogenese i et emneå administrere til emnet med behov derav en terapeutisk effektiv mengde av en sammensetning valgt fra gruppen bestående av formel (I) og formel (II), eller et farmasøytisk aksepterbart salt eller en ester derav, hvori fenyl er substituert ved X med en til fem halogenatomer valgt fra gruppen bestående av fluor, klor, brom og jod; og, Ri, R, R3, R4, Rs og Rer uavhengig valgt fra gruppen bestående av hydrogen og C-Calkyl; hvori C-Calkyl er valgfritt substituert med fenyl (hvori fenyl er valgfritt substituert med substituentene uavhengig valgt fra gruppen bestående av halogen, Ci-C4 alkyl, C-Calkoksy, amino, nitro og cyano).
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61027604P | 2004-09-16 | 2004-09-16 | |
| US69862505P | 2005-07-12 | 2005-07-12 | |
| US70724205P | 2005-08-11 | 2005-08-11 | |
| PCT/US2005/032861 WO2006033947A2 (en) | 2004-09-16 | 2005-09-15 | Use of 2-phenyl-1, 2-ethanediol- (di) carbamates for treating epileptogenesis and epilepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20071921L true NO20071921L (no) | 2007-06-12 |
Family
ID=36087909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20071921A NO20071921L (no) | 2004-09-16 | 2007-04-16 | Fremgangsmater for behandling av epileptogenese og epilepsi |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20060194873A1 (no) |
| JP (1) | JP2008513466A (no) |
| KR (1) | KR20070057939A (no) |
| CN (1) | CN101056629B (no) |
| AT (1) | ATE464044T1 (no) |
| AU (1) | AU2005287174B2 (no) |
| BR (1) | BRPI0515374A (no) |
| CA (1) | CA2580640A1 (no) |
| CO (1) | CO6382111A2 (no) |
| CR (1) | CR9053A (no) |
| DE (1) | DE602005020667D1 (no) |
| DK (1) | DK1809273T3 (no) |
| EA (1) | EA200700642A1 (no) |
| ES (1) | ES2342185T3 (no) |
| HR (1) | HRP20100304T1 (no) |
| IL (1) | IL181910A0 (no) |
| MX (1) | MX2007003278A (no) |
| NO (1) | NO20071921L (no) |
| NZ (1) | NZ553813A (no) |
| PT (1) | PT1809273E (no) |
| RS (1) | RS51269B (no) |
| WO (1) | WO2006033947A2 (no) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL148052A0 (en) * | 1999-08-10 | 2002-09-12 | Uab Research Foundation | Use of gaba antagonists for treatment of spastic disorders, convulsions, and epilepsy |
| MX2007004491A (es) * | 2004-10-15 | 2007-08-08 | Johnson & Johnson | Compuestos de carbamato para utilizar en el tratamiento de padecimientos neurodegenerativos. |
| PE20070325A1 (es) * | 2005-06-29 | 2007-05-12 | Alza Corp | Formas de dosificacion oral que comprenden compuestos derivados de carbamato |
| US20070021500A1 (en) * | 2005-07-12 | 2007-01-25 | Twyman Roy E | Methods for neuroprotection |
| US20070043120A1 (en) * | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
| WO2007144195A2 (en) | 2006-06-15 | 2007-12-21 | Schwarz Pharma Ag | Pharmaceutical composition with synergistic anticonvulsant effect |
| CN101657195A (zh) * | 2006-10-06 | 2010-02-24 | 詹森药业有限公司 | 氨基甲酸(s)-(+)-2-(2-氯代苯基)-2-羟基乙酯的新型晶体 |
| MX2009004798A (es) * | 2006-10-31 | 2009-08-12 | Janssen Pharmaceutica Nv | Tratamiento de los trastornos generalizados del desarrollo. |
| US9018253B2 (en) | 2010-07-02 | 2015-04-28 | Bio-Pharm Solutions Co., Ltd. | Phenylcarbamate compound and muscle relaxant containing the same |
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| EP2797880B1 (en) * | 2011-12-27 | 2017-03-01 | Bio-Pharm Solutions Co., Ltd. | Phenyl carbamate compounds for use in preventing or treating epilepsy |
| EP2968210B1 (en) * | 2013-03-12 | 2024-09-11 | Bio-Pharm Solutions Co., Ltd. | Phenyl carbamate compounds for use in preventing or treating pediatric epilesy |
| US9566261B2 (en) * | 2013-03-12 | 2017-02-14 | Bio-Pharm Solutions Co., Ltd. | Phenyl carbamate compound and a composition for preventing or treating a memory loss-related disease comprising the same |
| ES3059582T3 (en) * | 2016-02-29 | 2026-03-23 | Bio Pharm Solutions Co Ltd | Sulfamate derivative compounds, processes for preparing them and their uses |
| CN106053510A (zh) * | 2016-05-16 | 2016-10-26 | 山东省分析测试中心 | 一种基于氢核磁共振快速测定普瑞巴林原料药纯度的方法 |
| KR102421006B1 (ko) * | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도 |
| EP4193987A4 (en) * | 2020-08-06 | 2024-08-21 | SK Biopharmaceuticals Co., Ltd. | SOLID ORAL COMPOSITION COMPRISING A CARBAMATE COMPOUND AND PROCESS FOR ITS PREPARATION |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3313692A (en) * | 1958-04-21 | 1967-04-11 | Armour Pharma | Method of inducing calming and muscle relaxation with carbamates |
| US3265728A (en) * | 1962-07-18 | 1966-08-09 | Armour Pharma | Substituted phenethyl carbamates |
| US20010034365A1 (en) * | 1996-01-16 | 2001-10-25 | Choi Yong Moon | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| AU3304997A (en) * | 1996-05-31 | 1998-01-05 | Southern Illinois University | Methods of modulating aspects of brain neural plasticity by vagus nerve stimulation |
| CA2360258A1 (en) * | 1999-02-09 | 2000-08-17 | Timothy L. Macdonald | Felbamate derived compounds |
| US6627211B1 (en) * | 1999-07-26 | 2003-09-30 | Sk Corporation | Transnasal anticonvulsive compositions and modulated process |
| MXPA03007717A (es) * | 2001-02-27 | 2005-11-08 | Johnson & Johnson | Compuestos de carbamato para su uso en la prevencion o tratamiento de trastornos bipolares. |
| PL364640A1 (en) * | 2001-02-27 | 2004-12-13 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating bipolar disorder |
| PL364680A1 (en) * | 2001-02-27 | 2004-12-13 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating neurodegenerative disorders |
-
2005
- 2005-09-15 CA CA002580640A patent/CA2580640A1/en not_active Abandoned
- 2005-09-15 DE DE602005020667T patent/DE602005020667D1/de not_active Expired - Lifetime
- 2005-09-15 KR KR1020077008402A patent/KR20070057939A/ko not_active Ceased
- 2005-09-15 MX MX2007003278A patent/MX2007003278A/es active IP Right Grant
- 2005-09-15 HR HR20100304T patent/HRP20100304T1/hr unknown
- 2005-09-15 EA EA200700642A patent/EA200700642A1/ru unknown
- 2005-09-15 WO PCT/US2005/032861 patent/WO2006033947A2/en not_active Ceased
- 2005-09-15 NZ NZ553813A patent/NZ553813A/en not_active IP Right Cessation
- 2005-09-15 PT PT05810288T patent/PT1809273E/pt unknown
- 2005-09-15 AU AU2005287174A patent/AU2005287174B2/en not_active Expired - Fee Related
- 2005-09-15 CN CN2005800387418A patent/CN101056629B/zh not_active Expired - Fee Related
- 2005-09-15 BR BRPI0515374-3A patent/BRPI0515374A/pt not_active IP Right Cessation
- 2005-09-15 AT AT05810288T patent/ATE464044T1/de active
- 2005-09-15 ES ES05810288T patent/ES2342185T3/es not_active Expired - Lifetime
- 2005-09-15 JP JP2007532446A patent/JP2008513466A/ja active Pending
- 2005-09-15 RS RSP-2010/0264A patent/RS51269B/sr unknown
- 2005-09-15 DK DK05810288.0T patent/DK1809273T3/da active
- 2005-09-15 US US11/227,247 patent/US20060194873A1/en not_active Abandoned
-
2007
- 2007-03-13 IL IL181910A patent/IL181910A0/en unknown
- 2007-03-29 CO CO07031825A patent/CO6382111A2/es not_active Application Discontinuation
- 2007-04-13 CR CR9053A patent/CR9053A/es not_active Application Discontinuation
- 2007-04-16 NO NO20071921A patent/NO20071921L/no not_active Application Discontinuation
- 2007-11-15 US US11/940,710 patent/US20110152362A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007003278A (es) | 2007-10-08 |
| AU2005287174A1 (en) | 2006-03-30 |
| BRPI0515374A (pt) | 2008-07-22 |
| CO6382111A2 (es) | 2012-02-15 |
| EA200700642A1 (ru) | 2007-10-26 |
| WO2006033947A3 (en) | 2006-06-29 |
| CR9053A (es) | 2009-10-30 |
| CN101056629A (zh) | 2007-10-17 |
| WO2006033947A2 (en) | 2006-03-30 |
| KR20070057939A (ko) | 2007-06-07 |
| CN101056629B (zh) | 2012-01-11 |
| NZ553813A (en) | 2010-09-30 |
| DK1809273T3 (da) | 2010-08-02 |
| IL181910A0 (en) | 2007-07-04 |
| JP2008513466A (ja) | 2008-05-01 |
| RS51269B (sr) | 2010-12-31 |
| AU2005287174B2 (en) | 2012-01-12 |
| ES2342185T3 (es) | 2010-07-02 |
| DE602005020667D1 (de) | 2010-05-27 |
| CA2580640A1 (en) | 2006-03-30 |
| US20110152362A1 (en) | 2011-06-23 |
| HK1105583A1 (en) | 2008-02-22 |
| PT1809273E (pt) | 2010-05-10 |
| ATE464044T1 (de) | 2010-04-15 |
| HRP20100304T1 (hr) | 2010-09-30 |
| US20060194873A1 (en) | 2006-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20071921L (no) | Fremgangsmater for behandling av epileptogenese og epilepsi | |
| NO20080877L (no) | Fremgangsmater for behandling av substansrelaterte forstyrrelser | |
| YU67703A (sh) | Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja | |
| MY138156A (en) | Carbamate compounds for use in preventing or treating neurodegenerative disorders | |
| WO2007008562A3 (en) | Carbamate compounds for use in treating neurodegenerative disorders | |
| IL157590A0 (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
| TW200744575A (en) | Methods of treating epileptogenesis | |
| IL157594A0 (en) | Carbamate compounds for use in preventing or treating anxiety disorders | |
| MX2009004553A (es) | Metodos para el tratamiento de trastornos cocleares y vestibulares. | |
| EA200700871A1 (ru) | Способы нейропротекции | |
| TW200701978A (en) | Methods of treating epileptogenesis and epilepsy | |
| IL159847A0 (en) | Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain | |
| MY136733A (en) | Carbamate compounds for use in preventing or treating psychotic disorders | |
| CY1110672T1 (el) | Χρηση των 2- φαινυλ-1,2-αιθανοδιολης- (δι) καρβαμικων για θεραπεια επιληπτογενεσης | |
| MY149385A (en) | Methods for treating substance-related disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |